NCT04353284View on ClinicalTrials.gov

Camostat Mesylate in COVID-19 Outpatients

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

March 3, 2021

Study Completion Date

April 22, 2021

Conditions
COVID-19
Interventions
DRUG

Camostat Mesilate

Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.

OTHER

Placebo

Placebo taken orally, 4 times daily, for 7 days.

Trial Locations (1)

06511

Yale University, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT04353284 - Camostat Mesylate in COVID-19 Outpatients | Biotech Hunter | Biotech Hunter